Is Vistagen Therapeutics Inc (NASDAQ:VTGN)’s Fuel Running Low? Reports Show More Sellers

June 14, 2018 - By Hannah Black

The stock of Vistagen Therapeutics Inc (NASDAQ:VTGN) registered an increase of 5.1% in short interest. VTGN’s total short interest was 1.91 million shares in June as published by FINRA. Its up 5.1% from 1.82M shares, reported previously. With 394,000 shares average volume, it will take short sellers 5 days to cover their VTGN’s short positions. The short interest to Vistagen Therapeutics Inc’s float is 21.22%.

The stock decreased 3.54% or $0.05 during the last trading session, reaching $1.44. About 600,622 shares traded. VistaGen Therapeutics, Inc. (NASDAQ:VTGN) has declined 19.67% since June 14, 2017 and is downtrending. It has underperformed by 32.24% the S&P500.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system disorders. The company has market cap of $32.92 million. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It currently has negative earnings. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells.

More recent VistaGen Therapeutics, Inc. (NASDAQ:VTGN) news were published by: Seekingalpha.com which released: “Oppenheimer bullish on VistaGen; shares up 62%” on May 25, 2018. Also Nasdaq.com published the news titled: “VistaGen Therapeutics Issued Two Key US Patents for Treatment of Depression with AV-101” on June 13, 2018. Streetinsider.com‘s news article titled: “After-Hours Stock Movers 05/24: (VTGN) (NWY) (CAVM) Higher; (ZOES) (BGSF) (EGHT) Lower (more…)” with publication date: May 24, 2018 was also an interesting one.

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: